[Apolipoproteins are new and better risk indicators of myocardial infarction]

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Biochemistry

Context:

• Traditional lipid profiles, including LDL and HDL cholesterol, can be misleading for cardiac risk assessment.
• Apolipoproteins (apo) transport cholesterol and triglycerides in the blood.
• ApoB is found in atherogenic lipoproteins like LDL, while apoA-I is specific to HDL.

Purpose:

• To evaluate the efficacy of apolipoprotein measurements (apoB, apoA-I, apoB/apoA-I ratio) in assessing cardiac risk.
• To compare the predictive value of apoB and apoA-I with traditional lipid markers (LDL, HDL).
• To review evidence from epidemiological and clinical trials, including statin interventions.

Summary:

• ApoB, apoA-I, and the apoB/apoA-I ratio are more strongly associated with cardiac risk and clinical outcomes than LDL or HDL levels.
• Studies reviewed include prospective epidemiological and clinical trials using statins.
• The findings suggest apoB and apoA-I provide superior risk stratification.

Impact:

• Recommends apoB and apoA-I measurements for routine clinical practice due to their superior predictive value for cardiac events.
• Highlights the limitations of relying solely on total cholesterol, LDL, and HDL for cardiovascular risk assessment.
• Supports a shift towards apolipoprotein-based risk evaluation for improved patient management and outcomes.